Genomic Vision Stock

Genomic Vision EBIT

The EBIT of Genomic Vision (GV.PA) as of Sep 10, 2026 is -6.12 M EUR. In the previous year, EBIT was -4.90 M EUR — a change of 25.07% (lower).

EBIT

-6.12 MEUR

YoY

25.07%

Last updated:

In 2026, Genomic Vision's EBIT was -6.12 M EUR, a 25.07% increase from the -4.90 M EUR EBIT recorded in the previous year.

The Genomic Vision EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2015
-4.39 M EUR
Jan 1, 2016
-8.66 M EUR
Jan 1, 2017
-8.48 M EUR
Jan 1, 2018
-6.40 M EUR
Jan 1, 2019
-4.65 M EUR
Jan 1, 2020
-5.38 M EUR
Jan 1, 2021
-4.90 M EUR
Jan 1, 2022
-6.12 M EUR
The Genomic Vision EBIT history
YEAREBITYoY
-6.12 MEUR+25.07%
-4.90 MEUR-8.96%
-5.38 MEUR+15.66%
-4.65 MEUR-27.37%
-6.40 MEUR-24.48%
-8.48 MEUR-2.12%
-8.66 MEUR+97.22%
-4.39 MEUR+98.33%
-2.21 MEUR+101.27%
-1.10 MEUR-41.18%
-1.87 MEUR+92.78%
-970,000.00EUR
Access this data via the Eulerpool API

Genomic Vision Revenue

Genomic Vision Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2015
2.36 M EUR
-4.39 M EUR
-4.34 M EUR
Jan 1, 2016
1.57 M EUR
-8.66 M EUR
-8.61 M EUR
Jan 1, 2017
2.14 M EUR
-8.48 M EUR
-9.07 M EUR
Jan 1, 2018
1.11 M EUR
-6.40 M EUR
-6.90 M EUR
Jan 1, 2019
1.77 M EUR
-4.65 M EUR
-4.61 M EUR
Jan 1, 2020
1.08 M EUR
-5.38 M EUR
-5.18 M EUR
Jan 1, 2021
994,000.00 EUR
-4.90 M EUR
-5.00 M EUR
Jan 1, 2022
1.03 M EUR
-6.12 M EUR
-6.79 M EUR

Genomic Vision Margins

Genomic Vision stock margins

The Genomic Vision margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genomic Vision. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genomic Vision.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2015
95.51 %
-186.06 %
-183.81 %
Jan 1, 2016
52.00 %
-550.54 %
-547.55 %
Jan 1, 2017
33.02 %
-395.89 %
-423.68 %
Jan 1, 2018
-235.94 %
-575.11 %
-619.77 %
Jan 1, 2019
-100.56 %
-262.66 %
-260.34 %
Jan 1, 2020
-108.76 %
-496.03 %
-477.58 %
Jan 1, 2021
-122.94 %
-492.45 %
-502.82 %
Jan 1, 2022
-165.01 %
-596.69 %
-661.79 %

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Genomic Vision's EBIT

Genomic Vision's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Genomic Vision's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Genomic Vision's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Genomic Vision’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Genomic Vision stock

EBIT of Genomic Vision is -6.12 M EUR in 2026.

EBIT of Genomic Vision changed from -4.90 M EUR to -6.12 M EUR, representing a 25.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Genomic Vision historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Genomic Vision

All Key Metrics — Genomic Vision